L'Alerte : journal indépendant : politique, littéraire et commercial

12 novembre 19051905/11/12 (A9)-1905/11/12

Additional file 1: of HGF potentiates extracellular matrix-driven migration of human myoblasts: involvement of matrix metalloproteinases and MAPK/ERK pathway

A) depicts the mean fluorescence intensities (MFI) derived from cytofluorometry for detection of CD49d, CD49e, and CD49f integrin alpha-chains from myoblast cell lines. B) shows cytofluorometric histograms for CD56 immunodetection in CL25 and LHCN-M2 human myoblast clones. (TIFF 245 kb

Additional file 2: of HGF potentiates extracellular matrix-driven migration of human myoblasts: involvement of matrix metalloproteinases and MAPK/ERK pathway

Kinetic analysis showing the spread area and cellular circularity of human myoblasts (CHQ cells) adhered onto ECM protiens, with or without HGF. **p < 0.01 versus BSA; ***p < 0.001. GT gelatin; LN laminin-111; FN fibronectin. (TIFF 181 kb

Additional file 5: of HGF potentiates extracellular matrix-driven migration of human myoblasts: involvement of matrix metalloproteinases and MAPK/ERK pathway

Migration of human myoblast cell lines towards laminin-111 (LN) or Fibronectin (FN), in the presence or absence of HGF, with ou without it inhibitor (UO126). Graph bars represent means error standard, showing migration of LHCN-M2 (105 cells) and CL25 (5 × 104 cells) human myoblasts onto extracellular matrix protiens in the presence or not of 10 ng/ml HGF. Note that UO126 alone does not have any effect on cell migration, but it does block the enhancing effects of HGF upon LN- or FN-induced migration. ***p < 0.001. (TIFF 79 kb

Additional file 6: Figure S3. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

Higher numbers of CD49dhi T cells in fast, but not in slow, progressors DMD patients correlate with disease severity. (DOC 59 kb

Additional file 5: Figure S2. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

Lack of differences between DMD patients and healthy control in relative numbers of CD14/CD49dhi and CD19/CD49dhi cells. (DOC 69 kb

Additional file 1: Table S1. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

General characteristics of the DMD patients enrolled in the study of blood samples. (DOC 35 kb

Additional file 4: Figure S1. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

Gating procedures for cytofluorometric labeling of CD49d in freshly isolated leukocytes from the blood of normal subjects and Duchenne muscular dystrophy patients. (DOC 108 kb